Emergent Biosolutions INC 8-K filings

Emergent BioSolutions reported Q2 2026 results with increased revenues but a substantial net loss, prompting a restructuring plan aimed at $40 million in annual savings.

Emergent BioSolutions announced a $52.7 million contract modification from the U.S. government for its ACAM2000 smallpox and mpox vaccine.

Emergent BioSolutions reported Q1 2026 total revenues of $156.1 million, exceeding the high end of its guidance range.

Emergent BioSolutions Inc. reported the outcomes of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of key proposals.

Emergent BioSolutions Inc. announced the appointment of John D. Fowler, Jr., a veteran in healthcare and financial services, to its Board of Directors, effective March 1, 2026.

Emergent BioSolutions Inc. reported significant progress in its multi-year turnaround strategy for 2025, achieving strong adjusted EBITDA and improved operating margins, while providing a cautious outlook for 2026 with anticipated declines in profitability.

Emergent BioSolutions presents its multi-year transformation plan, highlighting significant debt reduction, improved profitability, and strategic growth initiatives at the J.P. Morgan Healthcare Conference.

Emergent BioSolutions announced a voluntary $100 million prepayment on its term loan, reducing gross debt by $275 million since 2023.

Emergent BioSolutions received U.S. FDA approval for drug product manufacturing of raxibacumab at its Winnipeg, Canada facility, advancing its transformation strategy.

Dr. Louis W. Sullivan will retire from Emergent BioSolutions' Board of Directors effective November 14, 2025, after 19 years of service.

Emergent BioSolutions Inc. reported third-quarter 2025 financial results exceeding revenue guidance and raised its full-year 2025 financial forecast, driven by strong MCM orders and sequential naloxone growth.

Emergent BioSolutions Inc. announced a $56 million contract modification to supply ACAM2000 smallpox and mpox vaccine to the U.S. government, boosting projected sales to over $120 million this year.

Emergent BioSolutions announced a $30 million contract modification from BARDA to supply additional doses of its CYFENDUS anthrax vaccine.

Emergent BioSolutions Inc. reported strong second quarter 2025 financial results, exceeding revenue guidance and raising full-year profitability outlook, driven by improved margins and strategic execution.

Emergent BioSolutions Inc. announced a $62.4 million contract modification from the U.S. Department of Health and Human Services to supply its Botulism Antitoxin (BAT), reinforcing the nation's biodefense capabilities.

Emergent BioSolutions Inc. has received preliminary court approval for a $15 million settlement, funded by insurers, to resolve multiple shareholder derivative actions, alongside significant corporate governance enhancements.

Emergent BioSolutions announces positive first-quarter results for 2025, marked by increased profitability and reaffirmed financial guidance for the year.

Emergent BioSolutions held its 2025 annual meeting, where stockholders elected directors, ratified the appointment of Ernst & Young LLP as the independent auditor, and approved executive compensation.

Emergent BioSolutions' Board of Directors has authorized a stock repurchase program of up to $50 million, signaling confidence in the company's strategy and future cash generation.

Emergent BioSolutions finalizes the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million, streamlining operations and retaining future manufacturing capacity.

Emergent BioSolutions divests its Baltimore-Bayview manufacturing site to Syngene International for $36.5 million, streamlining operations and retaining manufacturing access for future needs.

Emergent BioSolutions reports a decrease in Q4 revenue but a significant increase in Adjusted EBITDA, providing 2025 guidance with improved profitability.

Emergent BioSolutions presented at the 43rd Annual J.P. Morgan Healthcare Conference, outlining its turnaround plan and key achievements in financial stabilization and strategic focus.

Emergent BioSolutions acquires exclusive U.S. and Canadian commercial rights to Hikma Pharmaceuticals' KLOXXADO (naloxone HCl) Nasal Spray 8 mg to broaden its opioid overdose emergency treatment offerings.

Emergent BioSolutions has been awarded two contract modifications totaling $70 million for the supply of anthrax vaccines to the U.S. government.

Emergent BioSolutions announced a significant turnaround in its financial performance for the third quarter of 2024, marked by increased revenue, net income, and adjusted EBITDA, leading to raised full-year guidance.

Emergent BioSolutions has granted a one-time equity award of 15,000 restricted stock units to its CFO, Richard S. Lindahl, in recognition of his contributions to recent strategic initiatives.

Emergent BioSolutions has closed a new $100 million asset-backed revolving loan facility to support its multi-year transformation plan.

Emergent BioSolutions closed the issuance of 1,113,338 shares and determined the exercise prices for warrants as part of its Term Loan Agreement.

Emergent BioSolutions has successfully refinanced its debt with a new $250 million term loan, extending its maturity and improving its financial flexibility.